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Cardiac hypertrophyCaloric excess has been postulated to disrupt cardiac function via (i) the generation of toxic intermediates,
(ii) via protein glycosylation and (iii) through the generation of reactive oxygen species. It is now
increasingly being recognized that the nutrient intermediates themselves may modulate metabolic
pathways through the post-translational modiﬁcations of metabolic enzymes. In light of the high energy
demand of the heart, these nutrient mediated modulations in metabolic pathway functioning may play an
important role in cardiac function and in the capacity of the heart to adapt to biomechanical stressors. In this
review the role of protein acetylation and deacetylation in the control of metabolic programs is explored.
Although not extensively investigated directly in the heart, the emerging data support that these nutrient
mediated post-translational regulatory events (i) modulate cardiac metabolic pathways, (ii) integrate
nutrient ﬂux mediated post-translational effects with cardiac function and (iii) may be important in the
development of cardiac pathology. Areas of investigation that need to be explored are highlighted. This
article is part of a Special Issue entitled: Mitochondria and Cardioprotection.hondria and Cardioprotection.
B.V.Published by Elsevier B.V.1. Introduction
The modern scourges of obesity and type 2 diabetes mellitus
(T2DM) have multiple disease consequences including the potential
to reverse decades of medical therapeutics and interventions that
have diminished cardiac morbidity and mortality [1]. The cardiac
health effects of nutrient excess are epitomized by the strong
correlation between body mass index and the development of cardiac
hypertrophy [2,3] and heart failure [4]. However, whether caloric
excess directly perturbs myocardial contractile function and hyper-
trophy, independent of the systemic effects of obesity and diabetes
such as endothelial dysfunction, hypertension and hyperlipidemia, is
ﬁercely contested, and has been difﬁcult to delineate in epidemiologic
studies.
If caloric excess does perturb myocardial growth and function,
sequelae would be expected to manifest as direct perturbations in
cellular metabolic pathway biology in parallel with alterations in
cardiac pump functioning and/or in the cardiac growth program. A
reductionist approach can be employed to investigate the role of
nutrient perturbations on metabolic pathways and to link these to
effects to cardiomyocyte function. The focus of this review is on the
effects of nutrient intermediates NAD+/NADH and acetyl-CoA and
their role on post-translational modiﬁcations in linking metabolism,
mitochondrial biology and myocardial function. The hypothesisexplored contends that these intermediates indirectly and directly
modulate metabolism andmitochondrial function, which in turn, may
orchestrate changes in cardiac muscle function and growth. The
objective of this article is to review the current knowledge pertaining
to (i) the modulation in cardiac function in response to changes in
caloric load; (ii) the role of NAD+-linked biology to changes in
metabolic and mitochondrial function; (iii) the role of acetyl-CoA as a
signaling intermediate to modulate metabolic biology; and (iv) an
overview of evidence how these metabolic pathway mediated
regulatory effects alter cardiac hypertrophy and function. An
additional important energetic-dependent system that modulates
cardiac biology is the AMPK signaling system. The role of AMPK in
nutrient sensing and as a signaling modulator has recently been
extensively reviewed [5] and is not a primary focus in this article.
Additional mechanisms that orchestrate “nutrient” mediated pertur-
bations in cardiac and skeletal muscle metabolism and mitochondrial
function include lipotoxicity [6,7], the consequences of protein
glycosylation [8], and via caloric-excess mediated augmentation of
reactive oxygen species (ROS) [9,10] with subsequent detrimental
sequelae. These mechanisms are similarly not the focus of this review.2. Modulation in cardiac function with changes in dietary load
In order to establish whether “nutrients” themselves modulate
cardiac contractile function, proof of concept studies has been
performed at the extreme limits of nutrient levels. Experimental
and human studies are discussed here to show that at the
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aspects of cardiac metabolism and function.
Changes in fuel substrate levels appear to initially affect cardiac
relaxation or diastole. Diastolic dysfunction is deﬁned as abnormal-
ities in the relaxation phase of the cardiac mechanical cycle that
delays ventricular ﬁlling and can result in symptoms and signs of
heart failure [11]. Although diastolic dysfunction was initially
proposed to occur independently of systolic contractile dysfunction
it is now recognized that a relative degree of contractile dysfunction
accompanies ﬁlling/relaxation deﬁcits [11]. The effects of nutrient
biology on the continuum of diastolic and systolic function and
cardiac hypertrophy are reviewed.
2.1. Caloric restriction
The acute restriction in caloric intake provokes adipose tissue
lipolysis resulting in elevated levels of circulating non-esteriﬁed fatty
acids [12]. This metabolic intervention results in increased cardiac
exposure to fatty acids where incorporation of triglyceride content
into the myocardium can be measured by 1H-magnetic resonance
spectroscopy (1H-MRS). Human studies have been performed using
1H-MRS in parallel with cardiac functional imaging to correlate
changes in cardiac triglyceride content and ventricular pump
function. Fasting up to 3 days, or restriction of calories over the
same period, results in progressive uptake of triglycerides into the
myocardium with a triglyceride “dose-dependent” associated atten-
uation in diastolic relaxation [13,14]. Interestingly this acute triglyc-
eride-level-dependent attenuation in cardiac relaxation appears to be
independent of alterations in high-energy phosphate levels [13].
Longer term caloric restriction results in a reduction in circulating
free fatty acid and triglyceride levels [15,16]. This dietary intervention
results in both a reduction in cardiac triglyceride content and an
improvement in diastolic function in obese type 2 diabetic subjects
[16]. In otherwise healthy individuals long-term caloric restriction
additionally protects against age-associated decline in diastolic
function [17]. Unfortunately in this latter study, myocardial triglyc-
eride content was not measured and the contribution of changes in
triglyceride levels to this ameliorative phenotype was not shown.
Systemic changes including a reduction in blood pressure may have
also contributed to the preservation of cardiac relaxation in this study.
The validity of change in intracardiac triglyceride and themodiﬁcation
in cardiac function are further supported by a human study showing a
strong correlation between the age-associated increase in myocardial
triglyceride content and impaired diastolic relaxation [18].
2.2. The cardiac clock and metabolic and functional changes with diurnal
rhythm
A continuous ﬂux in substrate availability to the heart naturally
occurs during the feeding and fasting states associatedwith the sleep–
wake cycle and circadian rhythm. A link between the circadian clock,
cardiac metabolism and contractile function has recently begun to be
explored [19]. Here, it is intriguing to note that in rats cardiac
contractile function, glucose oxidation and oxygen consumption are
signiﬁcantly higher in the middle of the dark cycle compared to the
middle of the light cycle [20]. This period coincides with the feeding
period and correlates with the lowest circadian levels of circulating
non-esteriﬁed fatty acid levels [20].
2.3. Caloric overload
Chronic nutrient overload results in the development of obesity
and predisposes to insulin resistance and/or T2DM. These clinical
conditions predispose to cardiac dysfunction and animal models have
been interrogated to facilitate the investigation of the temporal effects
of obesity and T2DM on myocardial functioning and metabolism [9].The leptin-deﬁcient ob/ob mouse exhibits insulin resistance and
diabetes in association with profound obesity. At 11 weeks of age, ob/
ob mice demonstrate increased neutral lipid accumulation in the
heart with echocardiographic parameters consistent with diastolic
dysfunction [21] Furthermore, these mice have impaired mitochon-
drial respiratory capacity in association with diminished pyruvate
dehydrogenase activity and a restricted glucose-dependent oxidative
capacity response to increased workload [22]. In response to the
direct addition of fat as the fuel substrate, oxygen consumption is
enhanced, but at the expense of cardiac efﬁciency suggesting that the
cardiac mitochondria in ob/ob mice are susceptible to lipid-mediated
mitochondrial uncoupling [22]. Indeed, direct measurement of
mitochondrial proton leak in the db/db (leptin receptor loss-of-
function mutation) mice supports the existence of fatty acid induced
mitochondrial uncoupling with perturbed leptin signaling [23].
Further characterization of the db/db mice using an isolated working
heart model system shows classical features of diastolic dysfunction
as measured by an increased in the left ventricular end diastolic
pressure and increased myocardial stiffness [24]. These perturbations
are proposed to result from the diminution in myocardial efﬁciency as
measured by the ratio between cardiac output (work) and oxygen
consumed (MVO2). This excess in MVO2 was found to be exacerbated
with higher levels of fat as the substrate for cardiacmetabolism. db/db
mice additionally show diminished glucose uptake and an early
thickening of the myocardium in young mice, with progressive
systolic dysfunction with aging [25]. The metabolic underpinning of
these deﬁcits is supported in that overexpression of the glucose
transporter GLUT4 with concomitant increase in glucose oxidation
rescues cardiac contractile function in db/db mice [26,27].
Additional animal models that support caloric overload mediated
disruption of cardiac function include the Otsuka Long–Evans
Tokushima Fatty rats which show disrupted left ventricular diastolic
ﬁlling [28] and evidence that cardiac contractile dysfunction is
accelerated and mortality increased in hypertensive rats when they
are subject to a high carbohydrate-diet [29]. Moreover, high-fat
feeding of Wistar rats also evokes cardiac contractile dysfunction,
which appears to result from enhanced fatty acid uptake through
CD36 and intramyocellular triacylglycerol accumulation [30]. This
observation is further supported by a study showing that obese
Zucker rats fed a high-fat “Western diet” exhibit increased cardiac
triglyceride content within a week of this dietary intervention in
parallel with reduced cardiac contractile functioning. Longer term
exposure to this diet promotes fatty acid oxidation which correlates
with the prevention of further deterioration in cardiac function or in
progressive cardiac triglyceride accumulation [31]. Interestingly, a
role for genetic susceptibility to developing this dietary response is
inferred in that the Zucker lean control rats show a greater resistance
to cardiac triglyceride accumulation and no adverse effects on the
maintenance of cardiac power on this same diet [31].
Human subjects with diabetes or glucose intolerance similarly
have increased cardiac steatosis as evident by 1H-MRS [32].
Furthermore, the measurement of high-energy phosphates in diabetic
and non-diabetic subjects without clinical coronary artery disease and
normal echocardiographic studies indirectly suggest that diabetic
subjects can develop diminished cardiac energetics prior to evidence
of measureable cardiac dysfunction [33]. Moreover, obesity is
associated with evidence of cardiac hypertrophy and chamber
dilatation, although dissecting out the relative contribution of
nutrient excess from obesity associated effects on blood pressure
and leptin homeostasis is difﬁcult to delineate [34].
2.4. Caloric ﬂux and modiﬁcation in protein lysine-residue acetylation
The studies discussed above show that the modulation in cardiac
substrate exposure can have measureable effects on cardiac function
and structure. Additionally, calorie excess associated disease processes
1281M.N. Sack / Biochimica et Biophysica Acta 1813 (2011) 1279–1285associated with obesity and T2DM can similarly affect cardiac function,
although it should be reiterated that the relative contribution of
“nutrient” mediated effects in this biology is complicated by the
comorbidities associated with these systemic disorders.
Nutrient-intermediate mediated changes in metabolic pathway
biology are actively being explored and appear to function, in part, via
post-translational modiﬁcation of protein lysine-residues by acetyla-
tion [35]. The majority of investigation into this arena has occurred in
the liver, where changes in protein acetylation status have been
explored comparing fasting versus fed conditions. These studies
demonstrate that the lysine-residues of enzymes controlling the
spectrum of metabolic pathways employed to catabolize nutrients for
energy production are modiﬁed by acetylation [35,36] in a carbon
source-dependent fashion [35]. Interestingly, increasing glucose and
fatty acid levels resulted in the increased acetylation in mitochondrial
metabolic pathway enzymes [35], and conversely fasting results in the
global deacetylation of mitochondrial proteins [36].
As the activities of cytosolic andmitochondrial metabolic enzymes
are altered by the change in acetylation status [35,37], the regulatory
enzymes orchestrating these post-translational modiﬁcations may be
important in modulating nutrient handling and cardiac function.
Interestingly, the most characterized “nutrient”-dependent alteration
in this program is caloric restriction induced protein lysine-residue
deacetylation via the activation of the sirtuin family of deacetylase
enzymes. The biochemistry and biology of this enzymatic system have
recently been extensively reviewed [38,39] but will be brieﬂy
discussed in the context of cardiac metabolism, growth and
contractile function.
3. Sirtuin enzyme mediated metabolic protein deacetylation and
cardiac functional consequences
3.1. The sirtuin family of enzymes
In contrast to the class I, II and IV histone deacetylases, which are
zinc-dependent, the sirtuins are designated as class III deacetylases
and are NAD+-dependent enzymes. The founding member of these
enzymes is yeast Sir2, which was found to silences chromatin via
deacetylation of histones [40]. Sir2 enzymes have been shown to
mediate lifespan extension in yeast, worms and ﬂies and are
postulated to function, in part, via the modulation of mitochondrial
function [41]. Mammals have 7 sirtuin enzymes designated as SIRT1
through SIRT7. The mammalian sirtuins are phylogenetically divided
into ﬁve subclasses based on the homology of their 250 amino acid
core domain [42]. The mitochondrial enriched SIRT3 clusters with
SIRT1 and SIRT2 in subclass I. These three enzymes show closest
homology to yeast Sir2 and exhibit the most robust deacetylase
activity. The additional mitochondrial enriched sirtuins SIRT4 and
SIRT5 are assigned to subclasses II and III, and exhibit predominant
ADP-ribosyltransferase and weak deacetylase activity respectively
[43,44] and SIRT6 and SIRT7 are classiﬁed as subclass IV enzymes [42].
Furthermore, the sirtuin isoforms have distinct tissue distributions
and subcellular localizations [45]. With the exception of SIRT4 and
SIRT7, all other family members are robustly expressed in the heart
[46]. The subcellular localization of the sirtuins is probably a central
feature in dictating their biological targets. Furthermore, their
locations are not exclusive and may be dynamic under speciﬁc
conditions. For example, SIRT1 is exclusively nuclear during cardiac
embryogenesis and then displays both nuclear and cytoplasm
postnatal localization [47]. Similarly, the subcellular localization of
SIRT3 is predominantly in themitochondrial matrix [48–50], although
some studies suggest that SIRT3 is exclusively mitochondrial [51]
while others show nuclear and cytosolic locations in whole tissue
preparations [52] and following overexpression [46,53,54]. Whether
changes in the subcellular localization of SIRT3 are associated with
biological stressors, are tissue-speciﬁc [50,52] and/or result from thegenetic manipulation studies is not completely resolved [55]. SIRT2
appears to be exclusively cytoplasmic, SIRT5 in the inner mitochon-
drial membrane or matrix and SIRT6 and SIRT7 in the nucleus
[44,45,56].
3.2. NAD biochemistry
Sirtuin activation is directly linked to the energetic and redox
status of the cell as measured by the ratio of NAD+:NADH, by the
absolute levels of NAD and by the NAD+ catabolite nicotinamide [57–
59]. NAD+ is a cofactor in the deacetylation reaction whereby the
nicotinamide ribose is cleaved at its glycosidic bond to yield
nicotinamide and the ribose accepts the acetyl group from the sirtuin
substrate to produce O-acetyl-ADP-ribose. The biochemistry of this
metabolic intermediate is not the focus of this review, but is beginning
to be explored [60]. Interestingly, the nicotinamide generated in the
deacetylation reaction itself inhibits sirtuin activity and nicotinamide-
depletion during NAD+ biosynthesis inversely activates sirtuins [61].
In vertebrates de novo NAD+ biosynthesis is the minor NAD+
generation pathway, and uses tryptophan and nicotinic acid as
metabolic precursors. This pathway does, however, appear to be
induced by exercise and following the administration of peroxisome
proliferator activated receptor alpha (PPARα) agonists [62]. The
major pathway to generate NAD+ involves the salvage of NAD+ using
nicotinamide as the precursor. In mammals there are two interme-
diary steps in NAD+ salvage, initiated by the conversion of
nicotinamide to nicotinamide mononucleotide (NMN) via the
nicotinamide phosphoribosyltransferase (NAMPT) enzyme. Nicotin-
amide/nicotinic acid mononucleotide adenylyltransferase (NMNAT)
then converts NMN to NAD+. These biochemical pathways are most
well characterized in the nucleus and are pivotal for the activity of
SIRT1 [63]. Moreover, NAMPT has been identiﬁed as the rate-
controlling step in NAD+ biosynthesis in that overexpression of
Nampt but not Nmnat increased cellular NAD+ levels [63].
The investigation into the biology of NAD+ in the mitochondria
has begun to be explored, and the identiﬁcation of a mitochondrial-
enriched NMNAT isoform implicates that subcellular compartment-
speciﬁc functioning of NAD biosynthesis may be operational [64]. This
is further supported in that the metabolic stress of fasting increases
mitochondrial NAMPT with the concomitantly increase in mitochon-
drial NAD+ levels [65].
The regulation and role of this metabolic pathway in controlling
cardiac metabolism and contractile function have not been extensively
explored, although the transcript and protein levels of NAMPT are
downregulated in the murine heart in response to pressure overload-
induced cardiac hypertrophy and the overexpression of NAMPT in
cardiomyocytes increased cellular NAD+ and ATP levels [66]. Taken
together thesedatawould suggest anameliorative roleof this regulatory
pathway and of sirtuin activation in cardiac metabolism and in the
adaptation to pathologic hypertrophic growth. Further support of this
concept is that the administration of NAD+ to mice or primary
cardiomyocytes exposed to hypertrophic agonist simulation amelio-
rates the hypertrophic phenotype in parallel with the maintenance of
cellular ATP levels [67]. The activation of this NAD+-mediated anti-
hypertrophic program appears to function via SIRT3 mediated activa-
tion of the AMPK program, and the attenuation of redox stress [67]. The
direct metabolic consequences of this and their effect, if any, on the
hypertrophic program have not been ascertained. No data to date
appear to have explored the manipulation of the NAD+ metabolic
pathway and its effects on cardiac contractile functioning.
3.3. Sirtuin control of substrate metabolism and cardiac muscle function
It has been well established that cardiac substrate utilization is
altered with the development of cardiac hypertrophy and the
transition to heart failure [68,69]. This metabolic remodeling results
Fig. 1. Mitochondrial pathway targets of SIRT3. The metabolic pathways, protein
complexes and individual proteins deacetylated by SIRT3 are highlighted by asterisks.
In general, the deacetylation of these proteins results in increased protein/pathway
activation. The exception is the deacetylation of cyclophilin D (Cyp D), as this
modiﬁcation inhibits this protein to attenuate susceptibility to increased mitochondrial
permeability. Additional abbreviations: TCA—tricarboxylic acid; PDH—pyruvate dehy-
drogenase; I–IV—represent the complex of the election transfer chain; Fo and F1 are
components of ATP synthase; ANT—adenine nucleotide translocase, UCP—uncoupling
proteins, VDAC—voltage-dependent anion channel.
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source and an augmentation in the use of glucose to generate energy.
The role of this metabolic remodeling in this progressive pathophys-
iology is uncertain. Interestingly, the supplementation of fatty acids as
substrates can delay the onset of pressure-overload induced cardiac
hypertrophy and possibly delay the progression to heart failure
[70,71], in parallel with the maintenance of fatty acid oxidation [72].
Whether sirtuin biology regulates these programs is not known,
although a role of sirtuins in regulating substrate utilization is
increasingly becoming apparent.
Although the role of SIRT1 in regulating fat metabolism has been
quite extensively investigated, it has not directly been studied in the
heart. In skeletal muscle, under low nutrient conditions SIRT1
increases fatty acid oxidation and leads to a metabolic switch from
glucose oxidation to fatty acid oxidation [73]. In this nutrient limited
environment AMPK enhances SIRT1 activity by increasing cellular
NAD+ level, resulting in the deacetylation and modulation of cognate
substrates including PGC-1α, FOXO1 and FOXO3a to regulate skeletal
muscle energy metabolism [74]. In an apparent perpetuating cycle,
the deacetylation of AMPK kinase LKB1 by SIRT1 concordantly
increases AMPK activity [75,76]. Additionally, in a caloric excess
environment SIRT1 is downregulated in skeletal muscle in parallel
with the suppression of mitochondrial respiratory function [77]. In the
postnatal heart fatty acids make up the major carbon source for ATP
production [69]. From a nutrient perspective it is interesting to note
that SIRT1 overexpression protects cardiomyocytes from serum
starvation induced cell death [78]. Furthermore, the modest induction
of SIRT1 in the heart in transgenic mice prevents aging associated
cardiac dysfunction and protects against paraquat-induced oxidative
stress [79]. This ameliorative effect is “gene-dose dependent” as a very
high copy number of the SIRT1 transgene induces cardiomyopathy
and increases oxidative stress [79]. Whether the ameliorative effects
of SIRT1 in the heart function, in part, through the modulation of fat
metabolism has not been determined.
SIRT3 has recently been reported to promote mitochondrial fatty-
acid oxidation, in the heart and other tissues, through the deacetyla-
tion and activation of long chain acyl-CoA dehydrogenase (LCAD)
[80]. A direct link between SIRT3 controlled fatty acid oxidation,
cardiac hypertrophy and heart failure has not been established;
however, mice with genetic depletion of SIRT3 possess greater
susceptibility to angiotensin II induced cardiac hypertrophy compared
to wild type mice and an anti-hypertrophic effect of SIRT3 over-
expression functions, in part, via its reactive oxygen species
modulatory effects [81].
Although not directly related to cardiac metabolism or cardiac
contractile function several mitochondrial proteins have been
identiﬁed as SIRT3 targets which link SIRT3 to various metabolic
pathways. Acetyl-CoA synthetase 2 (AceCS2) was the ﬁrst mito-
chondrial proteins found to be deacetylated and activated by SIRT3
[82,83]. AceCS2 converts free acetate, which is generated from
endogenous cellular reactions or absorbed from the gut, into an
active metabolite acetyl-CoA for energy production through the TCA
cycle. Interestingly, AceCS2 activation plays an important role in
acetate conversion under ketogenic conditions such as diabetes. A
second enzyme regulating ketone body production, i.e., mitochon-
drial 3-hydroxy-3-methylglutaryl CoA synthase 2 is similarly
activated by SIRT3 to facilitate energy production under fasting
conditions [84]. In addition, other two mitochondrial matrix
proteins, GDH, an enzyme important for amino acid metabolism,
and isocitrate dehydrogenase 2 (IDH2), a key regulation enzyme for
TCA cycle are also deacetylated and activated by SIRT3 [50,56].
Interestingly, several components of the electron transfer chain
(ETC) have found to be regulated by SIRT3. For example, NDUFA9, a
subunit for ETC complex I [85], succinate dehydrogenase ﬂavopro-
tein (SdhA), the complex II subunit [86], and ATP synthase alpha
and beta subunits [87,88] were shown to interact with SIRT3.Interaction with SIRT3 increases both complex I and complex II
activities [85,86], implying that SIRT3 is a central player in energy
metabolism. Consistent with this, SIRT3 is found to regulate and
maintain tissue basal ATP levels in vivo [85]. SIRT3 activation
additionally modulates reactive oxygen species levels by activation
of MnSOD [89] and by increasing levels of reduced glutathione [90].
These effects on reactive oxygen species level modulation may
hypothetically have cardioprotective effects, although this too has
not been directly explored. One laboratory has shown that the
absence of SIRT3 predisposes to the spontaneous development of
cardiac hypertrophy [81]. However, in general SIRT3 knockout mice
have shown no obvious basal metabolic abnormalities [50],
suggesting that the regulatory role of SIRT3 is most likely
operational under certain “nutrient” stress conditions, such as
during caloric restriction and in response to caloric excess. The
mitochondrial metabolic pathways regulated by SIRT3 are schema-
tized in Fig. 1.
Again, although the metabolic component of their function has
not been directly ascertained, a role of SIRT2 and SIRT7 appears to be
operational in the cardiac derived cells and the heart respectively.
Although not directly explored in the intact heart, the cytosolic
sirtuin SIRT2 modulates mitochondrial function via the modulation
of mitochondrial pro-apoptotic proteins and via mitochondrial
antioxidant enzyme regulation [91,92]. SIRT7 resides in the nucleoli
and following its genetic depletion mice develop and die from
cardiac hypertrophy and an inﬂammatory cardiomyopathy [93]. The
absence of SIRT7 in primary murine cardiomyocytes enhances p53
acetylation, additionally leading to increased apoptosis and in-
creased susceptibility to oxidative and genotoxic stressors [93].
4. Metabolic protein acetylation
A counter-regulatory program to counterbalance sirtuin deacety-
lase function is less well established. However, in much the same way
as histone acetyltransferases (HATs) counterbalance the histone
deacetylases (HDACs), it is expected that sirtuin acetyltransferases
should exist. With respect to HATs and sirtuin acetyltransferase
enzymes, acetyl-CoA would be expected to be the essential cofactor
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has been succinctly demonstrated where excess glucose availability
has been shown to be result in the ATP-citrate lyase-dependent
generation of nuclear acetyl-CoA from citrate with the subsequent
acetylation of histones and the induction of genes encoding for
glucose uptake and metabolic enzymes [95].
The ﬁrst functional characterization of a sirtuin deacetylase
demonstrated that acetyl transferase general control of amino-acid
synthesis (GCN5) acetylates PGC-1β to inhibit its activity to counter
the deacetylation function of SIRT1 [96]. The inhibition of the
predominant cardiac PGC isoform, PGC-1α has similarly been
shown to be acetylated and inhibited by the nuclear transcriptional
coactivator and acetyltransferase p300 [97]. Although not directly
studied in the heart, one could propose that these or other
acetyltransferases could function to dampen the PGC regulated
mitochondrial biogenesis and β-oxidation enzymes programs central
to cardiac contractile functioning and stress resilience [98,99].
As acetyl-CoA is a predominant intermediate of both pyruvate
dehydrogenase and the mitochondrial fatty acid β-oxidation cycle it
would not be unreasonable that this metabolite may function within
mitochondria as a “sensor” of caloric excess. Indeed, dynamic regulation
of mitochondrial acetyl-CoA levels is suggested by its accumulation in
liver mitochondria following high-fat feeding and diabetes [100], and
excess glucose and fatty acids have been shown to increase the
acetylation of mitochondrial metabolic cycle proteins with a concom-
itant modulation of enzyme activities [35]. However, to date no
mitochondrial enriched acetyl transferase has been identiﬁed to employ
acetyl-CoA for protein acetylation and/or to counterregulate the
deacetylase actions of SIRT3. These proteins need to be identiﬁed and
characterized before this putative nutrient regulated program could be
investigated in the regulation mitochondrial function in general and
more speciﬁcally in the heart in response to nutrient load mediated
alterations in cardiac growth and function.5. Conclusions
There is increasing recognition that “nutrient” intermediates can
play an important role in regulating metabolic pathways via the
modulation of the acetylation status of metabolic enzymes. This
review highlights new areas of research and as importantly,
signiﬁcant deﬁcits in our knowledge of the role of caloric-load biology
in the modulation of cardiac substrate utilization and as to whether
these regulatory programs play a role in cardiac adaptation and
maladaptation. The schematic Fig. 2 shows proposed functioning of
these programs in the modulation of cardiac contractile function and
in response to hypertrophic stressors. The calorie excess scenario in
this schematic additionally highlights the consequences of excessFig. 2. Schematic of sirtuin mediated regulatory events under “caloric load” control and
proposed effects on cardiac function. The plus sign represents protein activation and the
minus sign, protein inhibition.nutrient availability as an innate cardiac “toxin”. It is also important to
recognize that the metabolic regulatory effects and the resulting
cardiac consequences of the change in metabolic enzyme acetylation
status probably function to ﬁne-tune these biomechanical and
bioenergetic interactions, versus operating in a binary fashion
displaying “all or nothing” effects. This is best illustrated where the
knockout of SIRT3 has a subtle phenotype with metabolic effects most
apparent under maximal activation of the deacetylase program [80].
Nevertheless, chronic alternations in “ﬁne-tuning” of metabolism that
may be operational in caloric excess conditions such as obesity and
T2DM probably still have profound effects on the high-energy
demand system orchestrating cardiac contractile function and its
adaptation to extra-cardiac biomechanical stressors. We look forward
to exciting advances in the understanding of this regulation as
additional targets of sirtuin biology are delineated. Finally, the
identiﬁcation and characterization of the sirtuin counter-regulatory
programs, especially in the modulation of metabolic enzymes remain
enigmatic and may be pivotal in our understanding of nutrient
mediated modulation in cardiac function.
Acknowledgments
M.N.S. is funded by the Division of Intramural Research of the
National Heart Lung and Blood Institute of the National Institutes of
Health.
References
[1] S. Capewell, E.S. Ford, J.B. Croft, J.A. Critchley, K.J. Greenlund, D.R. Labarthe,
Cardiovascular risk factor trends and potential for reducing coronary heart
disease mortality in the United States of America, Bull. World Health Organ, 88
120–130.
[2] O.J. Rider, J.M. Francis, M.K. Ali, J. Byrne, K. Clarke, S. Neubauer, S.E. Petersen,
Determinants of left ventricular mass in obesity; a cardiovascular magnetic
resonance study, J. Cardiovasc. Magn. Reson. 11 (2009) 9.
[3] O.J. Rider, S.E. Petersen, J.M. Francis, M.K. Ali, L.E. Hudsmith, M.R. Robinson, K.
Clarke, S. Neubauer, Ventricular hypertrophy and cavity dilatation in relation to
body mass index in females with uncomplicated obesity, Heart.
[4] S. Kenchaiah, J.C. Evans, D. Levy, P.W. Wilson, E.J. Benjamin, M.G. Larson, W.B.
Kannel, R.S. Vasan, Obesity and the risk of heart failure, N. Engl. J. Med. 347
(2002) 305–313.
[5] A.S. Kim, E.J. Miller, L.H. Young, AMP-activated protein kinase: a core signalling
pathway in the heart, Acta Physiol. (Oxf) 196 (2009) 37–53.
[6] A.R. Wende, E.D. Abel, Lipotoxicity in the heart, Biochim. Biophys. Acta 1801
(2010) 311–319.
[7] D.N. Brindley, B.P. Kok, P.C. Kienesberger, R. Lehner, J.R. Dyck, Shedding light on
the enigma of myocardial lipotoxicity: the involvement of known and putative
regulators of fatty acid storage and mobilization, Am. J. Physiol. Endocrinol.
Metab. 298 (2010) E897–E908.
[8] A.J. Smit, J.W. Hartog, A.A. Voors, D.J. van Veldhuisen, Advanced glycation
endproducts in chronic heart failure, Ann. N. Y. Acad. Sci. 1126 (2008) 225–230.
[9] M.N. Sack, Type 2 diabetes, mitochondrial biology and the heart, J. Mol. Cell.
Cardiol. 46 (2009) 842–849.
[10] I. Pagel-Langenickel, J. Bao, L. Pang, M.N. Sack, The role of mitochondria in the
pathophysiology of skeletal muscle insulin resistance, Endocr. Rev. 31 (2010)
25–51.
[11] A. Desai, J.C. Fang, Heart failure with preserved ejection fraction: hypertension,
diabetes, obesity/sleep apnea, and hypertrophic and inﬁltrative cardiomyopa-
thy, Heart Fail. Clin. 4 (2008) 87–97.
[12] R.B. Goldrick, J. Hirsch, Serial studies on themetabolism of human adipose tissue.
II. Effects of caloric restriction and refeeding on lipogenesis, and the uptake and
release of free fatty acids in obese and nonobese individuals, J. Clin. Invest. 43
(1964) 1793–1804.
[13] R.W. van der Meer, S. Hammer, J.W. Smit, M. Frolich, J.J. Bax, M. Diamant, L.J.
Rijzewijk, R.A. de, J.A. Romijn, H.J. Lamb, Short-term caloric restriction induces
accumulation of myocardial triglycerides and decreases left ventricular diastolic
function in healthy subjects, Diabetes 56 (2007) 2849–2853.
[14] S. Hammer, R.W. van der Meer, H.J. Lamb, M. Schar, R.A. de, J.W. Smit, J.A. Romijn,
Progressive caloric restriction induces dose-dependent changes in myocardial
triglyceride content and diastolic function in healthy men, J. Clin. Endocrinol.
Metab. 93 (2008) 497–503.
[15] L. Fontana, T.E. Meyer, S. Klein, J.O. Holloszy, Long-term calorie restriction is
highly effective in reducing the risk for atherosclerosis in humans, Proc. Natl
Acad. Sci. USA 101 (2004) 6659–6663.
[16] S. Hammer, M. Snel, H.J. Lamb, I.M. Jazet, R.W. van der Meer, H. Pijl, E.A.
Meinders, J.A. Romijn, R.A. de, J.W. Smit, Prolonged caloric restriction in obese
patients with type 2 diabetes mellitus decreases myocardial triglyceride content
and improves myocardial function, J. Am. Coll. Cardiol. 52 (2008) 1006–1012.
1284 M.N. Sack / Biochimica et Biophysica Acta 1813 (2011) 1279–1285[17] T.E. Meyer, S.J. Kovacs, A.A. Ehsani, S. Klein, J.O. Holloszy, L. Fontana, Long-term
caloric restriction ameliorates the decline in diastolic function in humans, J. Am.
Coll. Cardiol. 47 (2006) 398–402.
[18] R.W. van der Meer, L.J. Rijzewijk, M. Diamant, S. Hammer, M. Schar, J.J. Bax, J.W.
Smit, J.A. Romijn, R.A. de, H.J. Lamb, The ageing male heart: myocardial
triglyceride content as independent predictor of diastolic function, Eur. Heart
J. 29 (2008) 1516–1522.
[19] D.J. Durgan, M.E. Young, The cardiomyocyte circadian clock: emerging roles in
health and disease, Circ. Res. 106 (2010) 647–658.
[20] M.E. Young, P. Razeghi, H. Taegtmeyer, Clock genes in the heart: characterization
and attenuation with hypertrophy, Circ. Res. 88 (2001) 1142–1150.
[21] C. Christoffersen, E. Bollano, M.L. Lindegaard, E.D. Bartels, J.P. Goetze, C.B.
Andersen, L.B. Nielsen, Cardiac lipid accumulation associated with diastolic
dysfunction in obese mice, Endocrinology 144 (2003) 3483–3490.
[22] S. Boudina, S. Sena, B.T. O'Neill, P. Tathireddy, M.E. Young, E.D. Abel, Reduced
mitochondrial oxidative capacity and increased mitochondrial uncoupling
impair myocardial energetics in obesity, Circulation 112 (2005) 2686–2695.
[23] S. Boudina, S. Sena, H. Theobald, X. Sheng, J.J. Wright, X.X. Hu, S. Aziz, J.I. Johnson,
H. Bugger, V.G. Zaha, E.D. Abel, Mitochondrial energetics in the heart in obesity-
related diabetes: direct evidence for increased uncoupled respiration and
activation of uncoupling proteins, Diabetes 56 (2007) 2457–2466.
[24] O.J. How, E. Aasum, D.L. Severson, W.Y. Chan, M.F. Essop, T.S. Larsen, Increased
myocardial oxygen consumption reduces cardiac efﬁciency in diabetic mice,
Diabetes 55 (2006) 466–473.
[25] P. Yue, T. Arai, M. Terashima, A.Y. Sheikh, F. Cao, D. Charo, G. Hoyt, R.C. Robbins, E.
A. Ashley, J. Wu, P.C. Yang, P.S. Tsao, Magnetic resonance imaging of progressive
cardiomyopathic changes in the db/db mouse, Am. J. Physiol. Heart Circ. Physiol.
292 (2007) H2106–H2118.
[26] D.D. Belke, T.S. Larsen, E.M. Gibbs, D.L. Severson, Altered metabolism causes
cardiac dysfunction in perfused hearts from diabetic (db/db)mice, Am. J. Physiol.
Endocrinol. Metab. 279 (2000) E1104–E1113.
[27] L.M. Semeniuk, A.J. Kryski, D.L. Severson, Echocardiographic assessment of
cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice, Am. J.
Physiol. Heart Circ. Physiol. 283 (2002) H976–H982.
[28] K. Mizushige, L. Yao, T. Noma, H. Kiyomoto, Y. Yu, N. Hosomi, K. Ohmori, H.
Matsuo, Alteration in left ventricular diastolic ﬁlling and accumulation of
myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat
model, Circulation 101 (2000) 899–907.
[29] N. Sharma, I.C. Okere, B.R. Barrows, B. Lei, M.K. Duda, C.L. Yuan, S.F. Previs, V.G. Sharov,
A.M. Azimzadeh, P. Ernsberger, B.D. Hoit, H. Sabbah, W.C. Stanley, High-sugar diets
increase cardiac dysfunction and mortality in hypertension compared to low-
carbohydrate or high-starch diets, J. Hypertens. 26 (2008) 1402–1410.
[30] D.M. Ouwens, M. Diamant, M. Fodor, D.D. Habets, M.M. Pelsers, H.M. El, Z.C.
Dang, C.E. van den Brom, R. Vlasblom, A. Rietdijk, C. Boer, S.L. Coort, J.F. Glatz, J.J.
Luiken, Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat
diet is associated with elevated CD36-mediated fatty acid uptake and
esteriﬁcation, Diabetologia 50 (2007) 1938–1948.
[31] M. Burgmaier, S. Sen, F. Philip, C.R. Wilson, C.C. Miller III, M.E. Young, H.
Taegtmeyer, Metabolic adaptation follows contractile dysfunction in the heart of
obese Zucker rats fed a high-fat “Western” diet, Obesity (Silver. Spring) (2010).
[32] J.M. McGavock, I. Lingvay, I. Zib, T. Tillery, N. Salas, R. Unger, B.D. Levine, P.
Raskin, R.G. Victor, L.S. Szczepaniak, Cardiac steatosis in diabetes mellitus: a 1H-
magnetic resonance spectroscopy study, Circulation 116 (2007) 1170–1175.
[33] M. Scheuermann-Freestone, P.L. Madsen, D. Manners, A.M. Blamire, R.E.
Buckingham, P. Styles, G.K. Radda, S. Neubauer, K. Clarke, Abnormal cardiac
and skeletal muscle energy metabolism in patients with type 2 diabetes,
Circulation 107 (2003) 3040–3046.
[34] F.L. de las, A.D.Waggoner, B.S. Mohammed, R.I. Stein, B.V. Miller III, G.D. Foster, H.
R. Wyatt, S. Klein, V.G. Davila-Roman, Effect of moderate diet-induced weight
loss and weight regain on cardiovascular structure and function, J. Am. Coll.
Cardiol. 54 (2009) 2376–2381.
[35] S. Zhao, W. Xu, W. Jiang, W. Yu, Y. Lin, T. Zhang, J. Yao, L. Zhou, Y. Zeng, H. Li, Y. Li,
J. Shi, W. An, S.M. Hancock, F. He, L. Qin, J. Chin, P. Yang, X. Chen, Q. Lei, Y. Xiong,
K.L. Guan, Regulation of cellular metabolism by protein lysine acetylation,
Science 327 (2010) 1000–1004.
[36] S.C. Kim, R. Sprung, Y. Chen, Y. Xu, H. Ball, J. Pei, T. Cheng, Y. Kho, H. Xiao, L. Xiao,
N.V. Grishin, M. White, X.J. Yang, Y. Zhao, Substrate and functional diversity of
lysine acetylation revealed by a proteomics survey, Mol. Cell 23 (2006)
607–618.
[37] Y.Y. Lin, J.Y. Lu, J. Zhang, W. Walter, W. Dang, J. Wan, S.C. Tao, J. Qian, Y. Zhao, J.D.
Boeke, S.L. Berger, H. Zhu, Protein acetylation microarray reveals that NuA4
controls key metabolic target regulating gluconeogenesis, Cell 136 (2009)
1073–1084.
[38] Z. Lu, I. Scott, B.R. Webster, M.N. Sack, The emerging characterization of lysine
residue deacetylation on the modulation of mitochondrial function and
cardiovascular biology, Circ. Res. 105 (2009) 830–841.
[39] T. Finkel, C.X. Deng, R. Mostoslavsky, Recent progress in the biology and
physiology of sirtuins, Nature 460 (2009) 587–591.
[40] G. Blander, L. Guarente, The Sir2 family of protein deacetylases, Annu. Rev.
Biochem. 73 (2004) 417–435.
[41] L. Guarente, Mitochondria—a nexus for aging, calorie restriction, and sirtuins?
Cell 132 (2008) 171–176.
[42] R.A. Frye, Phylogenetic classiﬁcation of prokaryotic and eukaryotic Sir2-like
proteins, Biochem. Biophys. Res. Commun. 273 (2000) 793–798.
[43] M.C. Haigis, L.P. Guarente, Mammalian sirtuins—emerging roles in physiology,
aging, and calorie restriction, Genes Dev. 20 (2006) 2913–2921.[44] T. Nakagawa, D.J. Lomb, M.C. Haigis, L. Guarente, SIRT5 deacetylates carbamoyl
phosphate synthetase 1 and regulates the urea cycle, Cell 137 (2009) 560–570.
[45] B. Schwer, E. Verdin, Conserved metabolic regulatory functions of sirtuins, Cell
Metab. 7 (2008) 104–112.
[46] T. Shi, F. Wang, E. Stieren, Q. Tong, SIRT3, a mitochondrial sirtuin deacetylase,
regulates mitochondrial function and thermogenesis in brown adipocytes, J. Biol.
Chem. 280 (2005) 13560–13567.
[47] M. Tanno, J. Sakamoto, T. Miura, K. Shimamoto, Y. Horio, Nucleocytoplasmic
shuttling of the NAD+-dependent histone deacetylase SIRT1, J. Biol. Chem. 282
(2007) 6823–6832.
[48] B. Schwer, B.J. North, R.A. Frye, M. Ott, E. Verdin, The human silent information
regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine
dinucleotide-dependent deacetylase, J. Cell Biol. 158 (2002) 647–657.
[49] P. Onyango, I. Celic, J.M. McCaffery, J.D. Boeke, A.P. Feinberg, SIRT3, a human SIR2
homologue, is an NAD-dependent deacetylase localized to mitochondria, Proc.
Natl Acad. Sci. USA 99 (2002) 13653–13658.
[50] D.B. Lombard, F.W. Alt, H.L. Cheng, J. Bunkenborg, R.S. Streeper, R. Mostoslavsky,
J. Kim, G. Yancopoulos, D. Valenzuela, A. Murphy, Y. Yang, Y. Chen, M.D. Hirschey,
R.T. Bronson, M. Haigis, L.P. Guarente, R.V. Farese Jr., S. Weissman, E. Verdin, B.
Schwer, Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine
acetylation, Mol. Cell. Biol. 27 (2007) 8807–8814.
[51] H.M. Cooper, J.N. Spelbrink, The human SIRT3 protein deacetylase is exclusively
mitochondrial, Biochem. J. 411 (2008) 279–285.
[52] N.R. Sundaresan, S.A. Samant, V.B. Pillai, S.B. Rajamohan, M.P. Gupta, SIRT3 is a
stress-responsive deacetylase in cardiomyocytes that protects cells from stress-
mediated cell death by deacetylation of Ku70, Mol. Cell. Biol. 28 (2008)
6384–6401.
[53] Y. Nakamura, M. Ogura, D. Tanaka, N. Inagaki, Localization of mouse
mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with
SIRT5, Biochem. Biophys. Res. Commun. 366 (2008) 174–179.
[54] M.B. Scher, A. Vaquero, D. Reinberg, SirT3 is a nuclear NAD+-dependent histone
deacetylase that translocates to the mitochondria upon cellular stress, Genes
Dev. 21 (2007) 920–928.
[55] J. Bao, Z. Lu, J.J. Joseph, D. Carabenciov, C.C. Dimond, L. Pang, L. Samsel, J.P. McCoy
Jr., J. Leclerc, P. Nguyen, D. Gius, M.N. Sack, Characterization of the murine SIRT3
mitochondrial localization sequence and comparison of mitochondrial enrich-
ment and deacetylase activity of long and short SIRT3 isoforms, J. Cell. Biochem.
110 (2010) 238–247.
[56] C. Schlicker, M. Gertz, P. Papatheodorou, B. Kachholz, C.F. Becker, C. Steegborn,
Substrates and regulation mechanisms for the human mitochondrial sirtuins
Sirt3 and Sirt5, J. Mol. Biol. 382 (2008) 790–801.
[57] S.J. Lin, P.A. Defossez, L. Guarente, Requirement of NAD and SIR2 for life-span
extension by calorie restriction in Saccharomyces cerevisiae, Science 289 (2000)
2126–2128.
[58] R.M. Anderson, K.J. Bitterman, J.G. Wood, O. Medvedik, H. Cohen, S.S. Lin, J.K.
Manchester, J.I. Gordon, D.A. Sinclair, Manipulation of a nuclear NAD+salvage
pathway delays aging without altering steady-state NAD+levels, J. Biol. Chem.
277 (2002) 18881–18890.
[59] E.M. Dioum, R. Chen, M.S. Alexander, Q. Zhang, R.T. Hogg, R.D. Gerard, J.A. Garcia,
Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive
deacetylase sirtuin 1, Science 324 (2009) 1289–1293.
[60] L. Tong, J.M. Denu, Function and metabolism of sirtuin metabolite O-acetyl-ADP-
ribose, Biochim. Biophys. Acta (2010).
[61] K.J. Bitterman, R.M. Anderson, H.Y. Cohen, M. Latorre-Esteves, D.A. Sinclair,
Inhibition of silencing and accelerated aging by nicotinamide, a putative
negative regulator of yeast sir2 and human SIRT1, J. Biol. Chem. 277 (2002)
45099–45107.
[62] Y. Ito, R. Yonekura, K. Maruta, T. Koike, Y. Nakagami, K. Shibata, K. Saito, Y.
Nagamura, Tryptophan metabolism was accelerated by exercise in rat, Adv. Exp.
Med. Biol. 527 (2003) 531–535.
[63] J.R. Revollo, A.A. Grimm, S. Imai, The NAD biosynthesis pathway mediated by
nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian
cells, J. Biol. Chem. 279 (2004) 50754–50763.
[64] F. Berger, C. Lau, M. Dahlmann, M. Ziegler, Subcellular compartmentation and
differential catalytic properties of the three human nicotinamide mononucle-
otide adenylyltransferase isoforms, J. Biol. Chem. 280 (2005) 36334–36341.
[65] H. Yang, T. Yang, J.A. Baur, E. Perez, T. Matsui, J.J. Carmona, D.W. Lamming, N.C.
Souza-Pinto, V.A. Bohr, A. Rosenzweig, C.R. de, A.A. Sauve, D.A. Sinclair, Nutrient-
sensitive mitochondrial NAD+ levels dictate cell survival, Cell 130 (2007)
1095–1107.
[66] C.P. Hsu, N. Hariharan, R.R. Alcendor, S. Oka, J. Sadoshima, Nicotinamide
phosphoribosyltransferase regulates cell survival through autophagy in cardi-
omyocytes, Autophagy 5 (2009) 1229–1231.
[67] V.B. Pillai, N.R. Sundaresan, G. Kim, M. Gupta, S.B. Rajamohan, J.B. Pillai, S.
Samant, P.V. Ravindra, A. Isbatan, M.P. Gupta, Exogenous NAD blocks cardiac
hypertrophic response via activation of the SIRT3-LKB1-AMPK pathway, J. Biol.
Chem. (2009).
[68] M.N. Sack, T.A. Rader, S. Park, J. Bastin, S.A. McCune, D.P. Kelly, Fatty acid
oxidation enzyme gene expression is downregulated in the failing heart,
Circulation 94 (1996) 2837–2842.
[69] M.N. Sack, D.P. Kelly, The energy substrate switch during development of heart
failure: gene regulatory mechanisms (Review), Int. J. Mol. Med. 1 (1998) 17–24.
[70] I.C. Okere, M.E. Young, T.A. McElfresh, D.J. Chess, V.G. Sharov, H.N. Sabbah, B.D.
Hoit, P. Ernsberger, M.P. Chandler, W.C. Stanley, Low carbohydrate/high-fat diet
attenuates cardiac hypertrophy, remodeling, and altered gene expression in
hypertension, Hypertension 48 (2006) 1116–1123.
1285M.N. Sack / Biochimica et Biophysica Acta 1813 (2011) 1279–1285[71] J.M. Berthiaume, M.S. Bray, T.A. McElfresh, X. Chen, S.M. Azam, M.E. Young, B.D.
Hoit, M.P. Chandler, Myocardial contractile response to physiological stress
improves with high saturated fat feeding in heart failure, Am. J. Physiol Heart
Circ. Physiol.
[72] D.J. Chess, R.J. Khairallah, K.M. O'Shea, W. Xu, W.C. Stanley, A high-fat diet
increases adiposity but maintains mitochondrial oxidative enzymes without
affecting development of heart failure with pressure overload, Am. J. Physiol.
Heart Circ. Physiol. 297 (2009) H1585–H1593.
[73] Z. Gerhart-Hines, J.T. Rodgers, O. Bare, C. Lerin, S.H. Kim, R. Mostoslavsky, F.W.
Alt, Z. Wu, P. Puigserver, Metabolic control of muscle mitochondrial function and
fatty acid oxidation through SIRT1/PGC-1alpha, EMBO J. 26 (2007) 1913–1923.
[74] C. Canto, Z. Gerhart-Hines, J.N. Feige, M. Lagouge, L. Noriega, J.C. Milne, P.J.
Elliott, P. Puigserver, J. Auwerx, AMPK regulates energy expenditure by
modulating NAD+metabolism and SIRT1 activity, Nature 458 (2009)
1056–1060.
[75] X. Hou, S. Xu, K.A. Maitland-Toolan, K. Sato, B. Jiang, Y. Ido, F. Lan, K. Walsh, M.
Wierzbicki, T.J. Verbeuren, R.A. Cohen, M. Zang, SIRT1 regulates hepatocyte lipid
metabolism through activating AMP-activated protein kinase, J. Biol. Chem. 283
(2008) 20015–20026.
[76] F. Lan, J.M. Cacicedo, N. Ruderman, Y. Ido, SIRT1 modulation of the acetylation
status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated
protein kinase activation, J. Biol. Chem. 283 (2008) 27628–27635.
[77] I. Pagel-Langenickel, J. Bao, J.J. Joseph, D.R. Schwartz, B.S. Mantell, X. Xu, N.
Raghavachari, M.N. Sack, PGC-1alpha integrates insulin signaling, mitochondrial
regulation, and bioenergetic function in skeletal muscle, J. Biol. Chem. 283
(2008) 22464–22472.
[78] R.R. Alcendor, L.A. Kirshenbaum, S. Imai, S.F. Vatner, J. Sadoshima, Silent
information regulator 2alpha, a longevity factor and class III histone deacetylase,
is an essential endogenous apoptosis inhibitor in cardiac myocytes, Circ. Res. 95
(2004) 971–980.
[79] R.R. Alcendor, S. Gao, P. Zhai, D. Zablocki, E. Holle, X. Yu, B. Tian, T. Wagner, S.F.
Vatner, J. Sadoshima, Sirt1 regulates aging and resistance to oxidative stress in
the heart, Circ. Res. 100 (2007) 1512–1521.
[80] M.D. Hirschey, T. Shimazu, E. Goetzman, E. Jing, B. Schwer, D.B. Lombard, C.A.
Grueter, C. Harris, S. Biddinger, O.R. Ilkayeva, R.D. Stevens, Y. Li, A.K. Saha, N.B.
Ruderman, J.R. Bain, C.B. Newgard, R.V. Farese Jr., F.W. Alt, C.R. Kahn, E. Verdin,
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme
deacetylation, Nature 464 (2010) 121–125.
[81] N.R. Sundaresan, M. Gupta, G. Kim, S.B. Rajamohan, A. Isbatan, M.P. Gupta, Sirt3
blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent
antioxidant defense mechanisms in mice, J. Clin. Invest. 119 (2009)
2758–2771.
[82] W.C. Hallows, S. Lee, J.M. Denu, Sirtuins deacetylate and activate mammalian
acetyl-CoA synthetases, Proc. Natl Acad. Sci. USA 103 (2006) 10230–10235.
[83] B. Schwer, J. Bunkenborg, R.O. Verdin, J.S. Andersen, E. Verdin, Reversible lysine
acetylation controls the activity of the mitochondrial enzyme acetyl-CoA
synthetase 2, Proc. Natl Acad. Sci. USA 103 (2006) 10224–10229.
[84] T. Shimazu, M.D. Hirschey, L. Hua, K.E. Dittenhafer-Reed, B. Schwer, D.B.
Lombard, Y. Li, J. Bunkenborg, F.W. Alt, J.M. Denu, M.P. Jacobson, E. Verdin, SIRT3deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and
regulates ketone body production, Cell Metab. 12 (2010) 654–661.
[85] B.H. Ahn, H.S. Kim, S. Song, I.H. Lee, J. Liu, A. Vassilopoulos, C.X. Deng, T. Finkel, A
role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis,
Proc. Natl Acad. Sci. USA 105 (2008) 14447–14452.
[86] H. Cimen, M.J. Han, Y. Yang, Q. Tong, H. Koc, E.C. Koc, Regulation of succinate
dehydrogenase activity by SIRT3 in mammalian mitochondria, Biochemistry 49
(2010) 304–311.
[87] I.K. Law, L. Liu, A. Xu, K.S. Lam, P.M. Vanhoutte, C.M. Che, P.T. Leung, Y. Wang,
Identiﬁcation and characterization of proteins interacting with SIRT1 and SIRT3:
implications in the anti-aging and metabolic effects of sirtuins, Proteomics 9
(2009) 2444–2456.
[88] J. Bao, I. Scott, Z. Lu, L. Pang, C.C. Dimond, D. Gius, M.N. Sack, SIRT3 is regulated by
nutrient excess and modulates hepatic susceptibility to lipotoxicity, Free Radic.
Biol. Med. 49 (2010) 1230–1237.
[89] X. Qiu, K. Brown, M.D. Hirschey, E. Verdin, D. Chen, Calorie restriction reduces
oxidative stress by SIRT3-mediated SOD2 activation, Cell Metab. 12 (2010)
662–667.
[90] S. Someya, W. Yu, W.C. Hallows, J. Xu, J.M. Vann, C. Leeuwenburgh, M. Tanokura,
J.M. Denu, T.A. Prolla, Sirt3 mediates reduction of oxidative damage and
prevention of age-related hearing loss under caloric restriction, Cell 143 (2010)
802–812.
[91] F. Wang, M. Nguyen, F.X. Qin, Q. Tong, SIRT2 deacetylates FOXO3a in response to
oxidative stress and caloric restriction, Aging Cell 6 (2007) 505–514.
[92] E.G. Lynn, C.J. McLeod, J.P. Gordon, J. Bao, M.N. Sack, SIRT2 is a negative regulator
of anoxia-reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2
cells, FEBS Lett. 582 (2008) 2857–2862.
[93] O. Vakhrusheva, C. Smolka, P. Gajawada, S. Kostin, T. Boettger, T. Kubin, T. Braun,
E. Bober, Sirt7 increases stress resistance of cardiomyocytes and prevents
apoptosis and inﬂammatory cardiomyopathy in mice, Circ. Res. 102 (2008)
703–710.
[94] A.G. Ladurner, Chromatin places metabolism center stage, Cell 138 (2009)
18–20.
[95] K.E. Wellen, G. Hatzivassiliou, U.M. Sachdeva, T.V. Bui, J.R. Cross, C.B. Thompson,
ATP-citrate lyase links cellular metabolism to histone acetylation, Science 324
(2009) 1076–1080.
[96] T.J. Kelly, C. Lerin, W. Haas, S.P. Gygi, P. Puigserver, GCN5-mediated transcrip-
tional control of the metabolic coactivator PGC-1beta through lysine acetylation,
J. Biol. Chem. (2009).
[97] S. Nemoto, M.M. Fergusson, T. Finkel, SIRT1 functionally interacts with the
metabolic regulator and transcriptional coactivator PGC-1{alpha}, J. Biol. Chem.
280 (2005) 16456–16460.
[98] D.P. Kelly, R.C. Scarpulla, Transcriptional regulatory circuits controlling mito-
chondrial biogenesis and function, Genes Dev. 18 (2004) 357–368.
[99] C.J. McLeod, I. Pagel, M.N. Sack, The mitochondrial biogenesis regulatory
program in cardiac adaptation to ischemia—a putative target for therapeutic
intervention, Trends Cardiovasc. Med. 15 (2005) 118–123.
[100] S. Horie, M. Isobe, T. Suga, Changes in CoA pools in hepatic peroxisomes of the rat
under various conditions, J. Biochem. 99 (1986) 1345–1352.
